Studies have shown that neoadjuvant nivolumab may provide long-term benefits for people with non-small cell lung cancer.

Published Date: 17 Feb 2023

BACKGROUND: NSCLC is the most common and important cause of cancer worldwide. Assessment: The patient...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

La FDA ha approvato Talzenna per trattare il cancro alla prostata metastatico che non è resistente alla castrazione.

2.

How artificial intelligence could significantly improve the prognosis for cancer patients.

3.

Breast cancer surgery: Study finds overnight hospital stay not important for older patients

4.

High numbers of rural patients cross state lines for cancer care

5.

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot